Dr. Lekkala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1700 SW 7th St
Topeka, KS 66606Phone+1 785-295-8000
Summary
- Dr. Manidhar Reddy Lekkala is an established Internal Medicine physician specializing in Hematology/Oncology based in Topeka, KS. He completed his education in 2012 at M. Rampure Medical College. Dr. Lekkala currently serves as an Assistant Professor at the University of Kansas Health System. His research contributions to the medical field are documented in numerous publications, spanning topics from systemic adverse effects associated with immunotherapy to the management of fluoropyrimidine-induced cardiotoxicity. His noteworthy papers have generated citations from other publications, with one paper receiving 24 citations.
Education & Training
- Robert Packer Hospital/GuthrieResidency, Internal Medicine, 2015 - 2018
- M. Rampure Medical CollegeClass of 2012
Certifications & Licensure
- KS State Medical License 2021 - 2025
- PA State Medical License 2015 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 3 citationsIncidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan:Sanjana Mullangi, Manidhar Reddy Lekkala, Charumathi Raghu Subramanian, Omar Nemer, Jagmeet P. Singh
Journal of Investigative Medicine High Impact Case Reports. 2021-01-01 - 77 citationsA meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea.Safi U. Khan, Crystal Duran, Hammad Rahman, Manidhar Lekkala, Muhammad A Saleem
European Heart Journal. 2018-06-21 - 8 citationsImpact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancerBahar Moftakhar, Manidhar Lekkala, Myla Strawderman, Tae C Smith, Philip J. Meacham
Breast Cancer Research and Treatment. 2020-07-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: